Get the Daily Brief
Latest Biotech News
Tvardi’s STAT3 candidate fails Phase 2 – stock tumbles
Tvardi Therapeutics reported a Phase 2 failure for its STAT3 inhibitor in idiopathic pulmonary fibrosis after high dropout rates and efficacy that resembled placebo, triggering a sharp decline in...
BMS buys Orbital Therapeutics: $1.5B bet on in vivo cell therapy
Bristol Myers Squibb has agreed to acquire Orbital Therapeutics for $1.5 billion to secure an in vivo cell therapy program aimed at autoimmune disease. The deal positions BMS alongside other large...
Bio‑Techne and Oxford Nanopore extend partnership: clinical nanopore assays planned
Bio‑Techne expanded its collaboration with Oxford Nanopore Technologies to develop and commercialize a broader portfolio of targeted enrichment sequencing kits for screening and diagnosing...
DIAL promoter editing: programmable control creates stable transgene setpoints
Researchers published a programmable promoter-editing framework named DIAL in Nature Biotechnology that converts transient inputs into heritable, stable setpoints of transgene expression in...
Cambridge ‘hematoids’: lab-grown embryo models make blood stem cells
Scientists at the University of Cambridge reported creation of three‑dimensional embryo‑like structures—termed hematoids—that recapitulate aspects of very early human development and produce blood...
Radioligand therapy momentum: Biokin cleared for Lu‑177 trial in China
China’s NMPA cleared Sichuan Biokin to begin clinical trials of [177Lu]‑BL‑ARC001, advancing a radioligand candidate into the clinic. The clearance comes amid a broader revival of radioligand...
Senators press for patent clarity: PERA hearing spotlights biotech IP risk
Senators held a hearing on the Patent Eligibility Restoration Act (PERA), with proponents arguing the bill is essential to restore clarity after Supreme Court rulings that muddied patent...
BMS buys Orbital Therapeutics for $1.5 billion – in vivo cell therapy bet
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion to add an in vivo cell therapy program aimed at autoimmune disease to its pipeline. MedCity News reported the deal...
Excellergy raises $70 million – challenger to Xolair with multi-mechanism allergy drugs
Excellergy closed a $70 million Series A to advance a portfolio of multipronged allergy therapeutics the company says could outperform current biologics such as Xolair. Company statements and a...
Tvardi’s STAT3 drug flunks Phase 2 – trial hit by high dropouts and safety issues
Tvardi Therapeutics reported a Phase 2 failure for its STAT3 inhibitor TTI‑101, citing high dropout rates tied to side effects and lack of efficacy versus placebo. Financial market reactions were...
Regeneron to seek FDA approval: gene therapy restored hearing in NEJM children study
Regeneron announced plans to file for FDA approval after publishing New England Journal of Medicine data showing its gene therapy restored meaningful hearing in nine of 12 children born deaf from...
Gilead, Arcus report 27‑month OS from anti‑TIGIT cohort – Phase 3 stays on track
Gilead and Arcus presented mid‑stage data showing almost 27 months median overall survival for a digestive tract cancer cohort treated with an anti‑TIGIT regimen, data the companies say support...
Meta‑Flux raises $2 million seed – multiomics + neural nets to predict drug effects
Meta‑Flux closed a $2 million seed round to build a platform that integrates multiomics, neural networks and biological modeling to forecast therapeutic and safety outcomes preclinically. The...
Bio‑Techne expands Oxford Nanopore partnership: long‑read kits for heritable disorder testing through 2032
Bio‑Techne and Oxford Nanopore extended and broadened their collaboration to develop and commercialize targeted enrichment long‑read sequencing kits for screening and diagnosing heritable genetic...
Novo Nordisk shuts cell therapy program – CEO reshuffle trims pipeline focus
Novo Nordisk informed Endpoints News it will discontinue its cell therapy research as part of a wider restructuring under CEO Maziar Mike Doustdar. The company—known for diabetes and obesity...
Trogenix nets $95 million – AAV ‘Trojan horse’ platform enters clinic planning
Edinburgh‑based Trogenix announced a $95 million Series A to advance its Odysseus platform—AAV vectors carrying Synthetic Super Enhancers that activate therapeutic payloads selectively in cancer...
Programmable promoter editing: DIAL enables heritable, tunable transgene control
Two papers published online in Nature Biotechnology introduce DIAL, a programmable promoter‑editing framework that engineers synthetic promoters to generate heritable setpoints of transgene...
Regeneron to seek FDA approval after NEJM hearing gains; Moderna posts melanoma responses
Regeneron said it will pursue regulatory approval after an NEJM‑published study showed its gene therapy restored usable hearing in most treated children with a congenital form of deafness. The...
Trogenix raises $95m – AAV 'Trojan horse' platform moves toward clinic
Edinburgh‑based Trogenix closed a $95 million Series A to advance its Odysseus platform and push its lead glioblastoma programme toward a planned first‑in‑human entry in early 2026. Investors on...
DIAL programmable promoters: tunable transgene control unveiled – CRISPR screens expose quiescent cell regulators
Researchers published a Nature Biotechnology study introducing DIAL (Dynamically Editable Artificial Loci), a programmable promoter‑editing framework that enables graded, reversible control of...